Geron (GERN) Capital Expenditures (2010 - 2024)
Geron (GERN) posted Capital Expenditures of -$141000.0 for Q4 2024, down 7150.0% sequentially from $2000.0 in Q2 2024, and down 320.31% YoY from $64000.0 in Q1 2024.
Geron (GERN) Capital Expenditures (2010 - 2024) Analysis & Trends
Geron has reported Capital Expenditures for 15 years, with the latest figure at -$141000.0 in Q4 2024.
- Quarterly Capital Expenditures fell 320.31% year-over-year to -$141000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $680000.0 (down 18.07% YoY) and the FY2024 annual result came in at $680000.0, down 18.07% from the prior year.
- Capital Expenditures slipped to -$141000.0 in Q4 2024 per GERN's latest filing, from $2000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $5.5 million in Q2 2022 and troughed at -$5.2 million in Q3 2022.
- A 5-year average of $134157.9 and a median of $50000.0 in 2022 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 1608.84% in 2021, down 73550.0% in 2021.
- Over 5 years, Capital Expenditures stood at $11000.0 in 2020, then soared by 836.36% to $103000.0 in 2021, then surged by 35.92% to $140000.0 in 2022, then plunged by 54.29% to $64000.0 in 2023, then slumped by 320.31% to -$141000.0 in 2024.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$141000.0, $2000.0, and $819000.0 for Q4 2024, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -141,000.00 |
| Dec 31, 2024 | -141,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 819,000.00 |
| Mar 31, 2024 | 819,000.00 |
| Dec 31, 2023 | 64,000.00 |
| Dec 31, 2023 | 64,000.00 |
| Sep 30, 2023 | 192,000.00 |
| Sep 30, 2023 | 192,000.00 |
| Jun 30, 2023 | 2.49 Mn |
| Jun 30, 2023 | 2.49 Mn |
| Mar 31, 2023 | -1.92 Mn |
| Mar 31, 2023 | -1.92 Mn |
| Dec 31, 2022 | 140,000.00 |
| Dec 31, 2022 | 140,000.00 |
| Sep 30, 2022 | -5.22 Mn |
| Sep 30, 2022 | -5.22 Mn |
| Jun 30, 2022 | 5.46 Mn |
| Jun 30, 2022 | 5.46 Mn |